Results 91 to 100 of about 21,820 (216)
In Vitro Efficacy of Ceftazidime-avibactam Against blaOXA-48 Carrying Klebsiella pneumoniae Isolates
, 2023 Introduction: The healthcare burden of carbapenem-resistant Klebsiella pneumoniae (K. pneumoniae) infections is growing. The newly developed beta-lactam/beta-lactamase inhibitor combination, ceftazidime-avibactam, shows promise in the treatment of such ...
Haluk Vahaboğlu +8 more
core +1 more source
Review of ceftazidime-avibactam for the treatment of infections caused by pseudomonas aeruginosa
, 2021 Pseudomonas aeruginosa is an opportunistic Gram-negative pathogen that causes a range of serious infections that are often challenging to treat, as this pathogen can express multiple resistance mechanisms, including multidrug-resistant (MDR) and ...
da Cunha, C.A. +6 more
core +1 more source
Activity of aztreonam/avibactam and ceftazidime/avibactam against Enterobacterales with carbapenemase-independent carbapenem resistance [PDF]
Enterobacterales with carbapenemase-independent resistance to carbapenems are sometimes selected during therapy and, on rare occasions, cause outbreaks. Most have extended-spectrum or AmpC β-lactamases, together with changes to permeability or penicillin-
Vickers, Anna +3 more
core +1 more source
Population Pharmacokinetic Modelling of Ceftazidime and Avibactam in the Plasma and Epithelial Lining Fluid of Healthy Volunteers [PDF]
, 2018 Objectives: Our objective was to develop population pharmacokinetic (PK) models for ceftazidime and avibactam in the plasma and epithelial lining fluid (ELF) of healthy volunteers and to compare ELF concentrations to plasma PK/pharmacodynamic (PD ...
Dimelow, R +4 more
core +1 more source
PLoS ONENDM-producing carbapenem-resistant bacterial infections became a challenge for clinicians. Combination therapy of aztreonam and ceftazidime-avibactam is a prudent choice for these infections.
Salman Khan +8 more
doaj +1 more source
Ceftazidime-avibactam induced renal disorders: past and present
Frontiers in PharmacologyWith the increasing prevalence of multidrug-resistant Gram-negative bacterial pathogens worldwide, antimicrobial resistance has become a significant public health concern. Ceftazidime-avibactam (CAZ-AVI) exhibited excellent in vitro activity against many carbapenemase-producing pathogens, and was widely used for the treatment of various complicated ...
Yanrong Shi +6 more
openaire +3 more sources
Therapeutic drug monitoring of ceftazidime/avibactam: why one leg is not enough to run
Background: Therapeutic drug monitoring (TDM) is becoming an increasingly recommended approach for assessing optimal pharmacokinetic/pharmacodynamic (PK/PD) target attainment of ceftazidime/avibactam.
Gatti, Milo +2 more
core +1 more source
Current Medicine Research and PracticeBackground: The ceftazidime-avibactam combination is able to inhibit ESBLs, AmpCs and Class A carbapenemases and has been recommended for the treatment of complicated UTIs and ventilator-associated bacterial pneumonia.
Reena Rajan +2 more
doaj +1 more source
De novo infections caused by ceftazidime/avibactam-resistant KPC variants are rarely reported. We characterize the evolution of a KPC-8-producing Klebsiella pneumoniae strain involved in a primary infection without previous ceftazidime/avibactam ...
Mateo-Vargas, María Alejandra +5 more
core +1 more source
Infection and Drug Resistance, 2018 Stan D Atkin,1 Shadaan Abid,1 Michael Foster,1 Moumita Bose,1 Ashley Keller,1 Rita Hollaway,2 Helio S Sader,3 David E Greenberg,1,4 James D Finklea,1 Mariana Castanheira,3 Raksha Jain1,4 1Department of Internal Medicine, University of Texas Southwestern ...
Atkin SD +10 more
doaj